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Synopsis 25 
Background 26 
The antibiotic flucloxacillin is an established cause of liver injury. Despite this, there are a lack of 27 
published data on both the strength of association after adjusting for potential confounders, and the 28 
absolute incidence among different sub-groups of patients.  29 
Objectives 30 
To assess the relative and absolute risks of liver injury following exposure to flucloxacillin and 31 
identify subgroups at potentially increased risk.  32 
Methods 33 
A cohort study between the 1st January 2000 and the 1st January 2012 using the UK Clinical Practice 34 
Research Datalink, including 1046699 people with a first prescription for flucloxacillin (861962) or 35 
oxytetracycline (184737). Absolute risks of experiencing both symptom-defined (jaundice) and 36 
laboratory-confirmed liver injury within 1-45 and 46-90 days of antibiotic initiation were estimated.  37 
Multivariable logistic regression was used to estimate 1-45 day relative effects.   38 
Results 39 
There were 183 symptom-defined cases (160 prescribed flucloxacillin) and 108 laboratory-confirmed 40 
cases (102 flucloxacillin).  The 1-45 day adjusted risk ratio for laboratory-confirmed injury was 5.22 41 
(95% CI 1.64-16.62) comparing flucloxacillin with oxytetracycline use. The 1-45 day risk of 42 
laboratory-confirmed liver injury was 8.47 per 100000 people prescribed flucloxacillin (95% CI 6.64-43 
10.65). People who received consecutive flucloxacillin prescriptions had a 1-45 day risk of jaundice of 44 
39.00 per 100000 (95% CI 26.85- 54.77), while those aged over 70 receiving consecutive 45 
prescriptions had a risk of 110.57 per 100000 (95% CI 70.86-164.48). 46 
Conclusions 47 
The short-term risk of laboratory confirmed liver injury was more than 5-fold higher after a 48 
flucloxacillin prescription than an oxytetracycline prescription. The risk of flucloxacillin-induced liver 49 
injury is particularly high within those over the age of 70 and those who receive multiple 50 
flucloxacillin prescriptions.  The stratified risk estimates from this study could help guide clinical care.    51 
 
 
Introduction 52 
Fucloxacillin is an antibiotic of the penicillin class, that has a broad range of uses in the treatment of 53 
Gram-positive bacterial infections, including skin and soft tissue infections, respiratory tract 54 
infections, urinary-tract infections, meningitis and prophylaxis during surgery.1 First available in 55 
1960, case reports appeared in the 1980’s of an adverse drug reaction in which the patient 56 
developed serious liver injury, which in some cases could be fatal.2 While commonly and increasingly 57 
prescribed in the UK,3 flucloxacillin is not marketed in the U.S. and some European countries, where 58 
alternative therapies perceived to have a better safety profile are used (such as dicloxacillin).  59 
Previous work has shown flucloxacillin to be associated with liver injury at a frequency of 60 
approximately eight per 100000 people exposed within the general population.4-6 Liver injury may 61 
occur up to 45 days from initiation of treatment, can be prolonged and is characterised by a 62 
predominantly cholestatic pattern of liver test results, and symptoms including jaundice. A number 63 
of epidemiological studies have identified an association, with increased age, prolonged duration of 64 
use and female gender identified as possible risk factors.6-8 Despite this, there are a lack of available 65 
data either in the literature or prescribing information on (1) the strength of association after 66 
adjusting for potential confounders or (2) the absolute risk of either laboratory-confirmed or 67 
symptom-defined liver injury associated with flucoxacillin within these potentially high-risk groups.   68 
The aims of this study were (1) to measure the association between being prescribed flucloxacillin 69 
and liver-injury (compared with being prescribed oxytetracycline) after adjusting for potential 70 
confounders of the association and (2) to quantify the risk of both symptom-defined (jaundice) and 71 
laboratory-confirmed injury within both the general population and subgroups at potentially 72 
increased risk.  73 
 74 
 75 
  76 
 
 
Materials and Methods 77 
Study design 78 
A cohort analysis of the association between flucloxacillin and liver injury, with oxytetracyline as a 79 
comparator drug.  Oxytetracycline was selected as it is an antibiotic that is not considered to be 80 
hepatotoxic that, in the clinical context within which the study was set, is used for a number of the 81 
same conditions as flucloxacillin, including skin infections, respiratory tract infections and urinary 82 
tract infections (see supplementary data section 1). 83 
Setting  84 
The study was performed within the UK Clinical Practice Research Datalink (CPRD), which contains 85 
comprehensive anonymised diagnostic, prescribing and lifestyle records on patients from over 625 86 
NHS primary care practices from across the UK (approximately 12 million total patients, broadly 87 
representative of the UK population).9 Further information is provided in the supplementary data 88 
(section 1) and elsewhere.9   89 
Participants 90 
The cohort was selected from patients actively registered in the CPRD between the dates of 1st 91 
January 2000 and 1st January 2012. The exposed group was made up of people over the age of 18 92 
with at least one prescription for flucloxacillin and at least 6 months of research-quality prescription 93 
history in CPRD prior to their first recorded prescription of flucloxacillin (see supplementary data, 94 
section 1).  95 
Patients with diseases or conditions that were likely to cause liver-related symptoms in their CPRD 96 
record within 6 months prior to their first recorded flucloxacillin prescription were excluded (see 97 
supplementary data section 2), as were people with any liver test results that met the criteria for 98 
drug-induced-liver injury10 (Table 1) within the previous 6 months. Women who were pregnant at 99 
the time of their first recorded flucloxacillin prescription were also excluded (in order to avoid liver 100 
symptoms caused by cholestasis in pregnancy). 101 
People prescribed oxytetracycline were selected as the comparator group, as oxytetraycline is an 102 
antibiotic with a similar range of indications to flucloxacillin that is not considered to cause liver 103 
injury.6 The exclusion criteria applied to the oxytetracycline group were the same as in the group 104 
exposed to flucloxacillin. 105 
 
 
Ethics 106 
Ethical approval was obtained from the Clinical Practice Research Datalink Independent Scientific 107 
Advisory Committee (approval number 12_049) and the LSHTM Research Ethics Committee 108 
(approval number 6215). 109 
Exposures, outcomes and co-variates 110 
Exposures 111 
Exposures were determined from CPRD prescription records. Based on results from previous studies 112 
suggesting injury may occur within a period of 6 weeks after flucloxacillin initiation,5, 6 a person was 113 
considered exposed and at risk for 45 days after the start of a first prescription for flucloxacillin or 114 
oxytetracycline. The date of the first prescription was the index date, and people receiving both 115 
drugs on the index date were included in the flucloxacillin group only. Anyone who received 116 
oxytetracycline on their index date but then received flucloxacillin within 45 days was reassigned to 117 
the flucloxacillin group, and their index date updated appropriately. A categorical number of 118 
flucloxacillin prescriptions variable was created, that recorded how many prescriptions for 119 
flucloxacillin an individual received between their index date and the earliest of: an outcome event, 120 
an exclusion event, transfer out of the database, death or day 45. For those in the exposed to 121 
flucloxacillin group, a (comparator) day 46-90 exposure period was also included for analysis. 122 
Outcomes 123 
Diagnostic terms, codelists and laboratory parameters for the outcome were selected based upon a 124 
review of 12 studies6, 11-21 identified by a systematic literature review performed for a previous study 125 
on liver injury.22  Final review of outcome definitions was performed by a member of the study team 126 
who is a General Practitioner and Professor in Clinical Epidemiology (LS), and a list of final terms is 127 
provided in the supplementary data (section 3).  128 
Assignment of outcome status was performed blinded to drug exposure status. Initially, potential 129 
cases were selected as people with any of a relatively broad list of liver-related diagnoses 130 
(supplementary data section 3) within the 90-day period after their index date (Figure 1). The 1-90 131 
day period was searched (rather than just the 1-45 day risk period) because for those prescribed 132 
flucloxacillin, we wanted to compare the risk of injury in the 46-90 day period with that of the 1-45 133 
day period.  Any liver test results for Bilirubin (Bil), Alkaline Phosphatase (ALP) and Alanine 134 
Aminotransferase (ALT) recorded within the 1-90 day period were then identified for these potential 135 
cases. Blood levels of these enzymes taken from the same blood sample are standard parameters for 136 
indicating and classifying drug-induced liver injury based upon the R-value (a ratio of ALT to ALP, 137 
detailed in Table 1). Data management was performed to obtain R values as detailed previously.22   138 
 
 
The R-values and Read codes were then used to define the following two potential liver injury case 139 
statuses: 140 
(1) Symptom-defined case: people who had a liver-related diagnosis code within the 90-day 141 
period following the index date for any jaundice related diagnosis or symptom (see 142 
supplementary data section 3)  143 
(2) Laboratory-confirmed case: people who had both of the following within the 90-day period 144 
following the index date (1) any of the liver-related diagnoses detailed in supplementary 145 
data section 3 and (2) a liver test result indicative of DILI (Table 1).  146 
A symptom-only (jaundice) defined case definition was included due to the unavailibility of 147 
laboratory test results from secondary care within CPRD, meaning that reliance on only laboratory 148 
test results to define cases may underascertain the number of cases.22  149 
The case-date for final symptom-defined cases was the date of jaundice, while for final laboratory-150 
confirmed cases, it was the latest of the liver-related diagnosis or laboratory test result indicating 151 
DILI (Figure 1). The full electronic health record of all potential cases for the period from 6 months 152 
prior to the index date up until the case date was then reviewed by a clinician (AR), blinded to drug 153 
exposure status. Potential cases without any more likely causes of liver injury were designated as 154 
cases, while those with a more likely cause or liver-related symptoms occurring prior to the index 155 
date were considered to be exclusions, and either excluded from the analysis completely (if the 156 
exclusion event was prior to their index date) or were kept in the analysis but designated as non-157 
cases (if the exclusion event happened after their index date but prior to their  158 
case date).   159 
In order to assess the performance of our case detection method against an established method for 160 
assessing causality of drug-induced liver injury, we applied the RUCAM/CIOMS causality assessment 161 
method23 to each of the laboratory-confirmed cases (see supplementary data section 3b). 162 
Co-variates and risk factors 163 
Results of previous studies and a causal diagram were used to assist with the selection of co-variates 164 
for the causal analysis. Age, gender, smoking, ethnicity, BMI, alcohol intake, socioeconomic status 165 
(SES), use of other drugs known to cause liver injury and calendar period were all included as 166 
potential measurable confounders. Further details are provided in supplementary data section 4a. 167 
Potential risk factors for increased susceptibilty to flucloxacillin-induced liver injury were selected 168 
based on the results of previous studies6-8 and included gender, age, and number of prescriptions. 169 
 
 
Statistical analysis 170 
Descriptive analysis 171 
Co-variates were tabulated by exposure status, before the number of cases within the 1-90 day 172 
period within each drug-exposure group was calculated. For the flucloxacillin group, the proportion 173 
of type of liver injury (hepatocellular versus cholestatic), characteristic symptoms of cases and 174 
median time from first prescription until case assignment were also tabulated.  175 
Overall risk of liver injury 176 
The 1-45 day risk of liver injury for each drug was calculated by dividing the total number of events 177 
within the 45 day period after the index date by the number of patients in each exposure group 178 
(Figure 1). 95% confidence intervals were calculated on the basis of a Poisson distribution of injury 179 
events within each exposure group and the risk of liver injury occurring per 100000 people within 180 
each of the exposure groups was tabulated. The risk of liver injury in the 46-90 day period after 181 
exposure to flucloxacillin was also calculated (Figure 1). 182 
Association between flucloxacillin and liver injury 183 
For the analysis of the association between flucloxacillin and liver injury, all relative effects were 184 
calculated as odds ratios, which given the rarity of the outcomes under study were interpreted as 185 
risk ratios24 (and will be referred to as such subsequently in this article).    186 
Crude risk ratios comparing the risk of liver injury during the 1-45 day period after a first prescription 187 
of flucloxacillin to the risk during the 1-45 day after a first prescription of oxytetracycline (Figure 1) 188 
were obtained. A logistic regression model was then constructed, with potential confounders 189 
included as informed by the causal diagram, in order to estimate an overall adjusted risk ratio for the 190 
effect of flucloxacillin on liver injury. 191 
Analysis of risk factors for flucloxacillin-induced liver injury 192 
Risks per 100000 people exposed to flucloxacillin and multivariable adjusted risk ratios were 193 
calculated and tabulated across all categories of each potential risk factor, with tests-for-trend 194 
applied where appropriate. Graphs were plotted to illustrate the change in risk across categories for 195 
potential risk factors shown to increase susceptibility to injury.   196 
Missing data and sensitivity analyses 197 
A description of the handling of missing data is provided in the supplementary data (section 4b).   198 
The following sensitivity analyses were performed: (1) removing those on co-fluampicil (2) removing 199 
those in the heaviest drinking category (3) removing people prescribed both flucloxacillin and 200 
oxytetracycline and (4) considering people with exclusion codes between drug prescription and an 201 
outcome event as cases.  202 
 
 
All analysis was performed using STATA (StataCorp LP, version 14.0). 203 
Results 204 
Participants 205 
Between the dates of 1st January 2000 and 1st January 2012 1073894 people aged 18 years and over 206 
were identified in CPRD who received a first prescription for either flucloxacillin or oxtetracycline 207 
and had been registered in the database for at least 6 months (Figure 2). 27156 people were 208 
subsequently removed as they did not meet the necessary eligibility criteria, leaving 1046738 209 
patients in the cohort. An additional 39 were found to have reasons for exclusion during detailed 210 
potential case review, leaving a final cohort of 1046699 people for analysis.  211 
Descriptive data 212 
Background characteristics of participants are shown in Table 2. There were 861962 people 213 
prescribed flucloxacillin and 184737 prescribed oxytetracycline. 56% of those prescribed 214 
oxytetracycline were female, compared with 54% of those prescribed flucloxacillin, and a higher 215 
proportion of those in the oxytetracycline group (55%) had an index date prior to 2006 than in the 216 
flucloxacillin group (48%). Oxytetracycline patients included a higher proportion of people on other 217 
drugs likely to cause liver injury than flucloxacillin patients (81% versus 52%). There was no 218 
difference in recorded ethnicity between the groups, and minimal differences in the distribution of 219 
all other characteristics between exposure groups. Ethnicity data was missing for 37% of the cohort. 220 
Description of liver injury cases 221 
Within 90 days from the index prescription, there were 183 symptom-defined cases (169 in the 222 
exposed to flucloxacillin group) and 108 laboratory-confirmed cases (102 in the exposed to 223 
flucloxacillin group). The type of liver injury within cases exposed to flucloxacillin was primarily (pure 224 
or mixed) cholestatic (69% of cases), and the median time from first flucloxacillin prescription until 225 
symptom-defined case assignment was 38 days (IQR 27–47), increasing to 40 days (IQR 32–48) for 226 
laboratory-confirmed cases (supplementary data section 5, Table S1).   227 
Risk of liver injury associated with flucloxacillin 228 
Table 3 shows absolute risk figures and both crude and multivariable adjusted results of the 229 
association between flucloxacillin and liver injury (compared with oxytetracycline).   230 
There were 73 out of 861962 people prescribed flucloxacillin with laboratory-confirmed liver injury 231 
within the 45-days after prescription, giving a 1-45 day risk of flucloxacillin-induced liver injury of 232 
8.47 cases per 100000 people (95% CI 6.64–10.65).  The risk of laboratory-confirmed injury for those 233 
exposed to oxytetracycline within the same time period was 1.62 per 100000 people (95% CI 3.35–234 
4.75), while the risk within those in the flucloxacillin group within the 46–90 day period from first 235 
 
 
prescription was 3.45 per 100000 (95% CI 2.31–4.95) (data not shown). For the case definition 236 
requiring only a symptom or diagnosis of jaundice (symptom-defined), the risk of liver injury within 237 
the 1-45 day period for those prescribed flucloxacillin was almost double that of the laboratory 238 
confirmed case definition (14.15 per 100 000, 95% CI 11.75–16.92) (Table 3).  239 
The crude risk ratio for the association between flucloxacillin and laboratory-confirmed liver injury 240 
was 5.22 (95% CI 1.65–16.57). There was no change in this estimate following multivariable 241 
adjustments (RR 5.22, 95% CI 1.64–16.62). The multivariable risk ratio for the symptom-defined 242 
outcome was lower than the laboratory-confirmed estimate, but had narrower confidence intervals 243 
(RR 3.73, 95% CI 1.73–8.03).    244 
Risk factors for flucloxacillin-induced liver injury 245 
There was strong evidence that increasing age was a risk factor for flucloxacillin-induced liver injury 246 
(p test-for-trend<0.001 for both symptom-based and laboratory confirmed outcomes), with a 247 
marked increase in the 1-45 day risk of injury in those over the age of 70 (e.g. multivariable-adjusted 248 
RR for laboratory-confirmed liver injury comparing those in the 70-79 year old age group with those 249 
aged 18-49: 23.26, 95% CI 7.88–68.67) (Table 4). There was also strong evidence for an increased 1-250 
45 day risk of injury with increasing number of prescriptions (p test-for-trend<0.001), with people 251 
receiving 3 or more prescriptions within the 1-45 day risk period experiencing 9.37 times the 1-45 252 
day risk of laboratory-confirmed injury (95% CI 4.40 – 19.95) than those receiving a single 253 
prescription within this period, after adjusting for age, gender and concomitant prescriptions for 254 
other causes of liver injury. For gender, there was a suggestion across both outcomes that females 255 
had a slightly increased risk of injury, although the 95% CI did not rule out a decreased risk (e.g. 256 
multivariable RR for symptom-based injury comparing females to males: 1.43, 95% CI 0.98–2.08). 257 
Considering the absolute 1-45 day risk per 100000 people exposed to flucloxacillin, the risk of 258 
jaundice in the 18-49 year-old age group was 2.87, 95% CI 1.53-4.90, increasing to 14.71 (95% CI 259 
8.86-22.98) in the 50-59 year old age group (Table 4 and Figure 3A). Within those over the age of 70, 260 
the absolute risk of jaundice was 45.30 per 100000 people (95% CI 35.69-56.69). In the overall 261 
population the risk of jaundice for those receiving a single prescription was 11.45 (95% CI 9.19-262 
14.09), increasing to 78.60 per 100000 (95% CI 33.94–154.82) within people receiving three or more 263 
flucloxacillin prescriptions (Table 4 and Figure 3B). People over the age of 70 receiving three or more 264 
prescriptions had a risk of jaundice of 163.83 (95% CI 53.21-381.9) (Figure 3B), while over 70 yr olds 265 
receiving 2 or more had a risk of 110.57 per 100000 (95% CI 66.35-154.79).  Risk figures for 266 
 
 
laboratory-confirmed injury were generally smaller in magnitude but demonstrated similar changes 267 
by age group and increasing number of prescriptions (Table 4 and Figure 3A).   268 
Performance of case definition compared to the RUCAM/CIOMS method 269 
The RUCAM/CIOMS method23 classified 63/73 (86%) of laboratory-confirmed cases from this study 270 
as “Probable (flucloxacillin) ADR” (see supplementary data section 3b for description of categories).  271 
The remaining 10/73 (14%) were classified as “Possible (flucloxacillin) ADR”. Of these, 5 were under 272 
the RUCAM/CIOMS age risk factor cut-off of 55 years old, with the remaining 5 having a prescription 273 
record for another drug that may have been more likely to have caused the observed injury. Within 274 
1-45 day laboratory-confirmed cases over the aged of 70, 91% (42/46) were classified as 275 
RUCAM/CIOMS probable.   276 
Pattern of liver injury by age 277 
We performed a post-hoc analysis of the 73 people exposed to flucloxacillin with laboratory-278 
confirmed liver injury to investigate whether the pattern of liver injury associated with flucloxacillin 279 
use varied by age group. 38 of the 46 people aged 70 years or over had a cholestatic type of injury 280 
(83%, 95% CI 71% - 94%), compared with 15 out of 27 under the age of 70 (56%, 95% CI 35% - 76%,  281 
Mann Whitney test p=0.01).  282 
Sensitivity analyses and missing data 283 
None of the sensitivity analyses performed had anything other than a negligible impact on the 284 
results obtained. There was minimal difference between univariable analysis results obtained using 285 
complete records compared to the multiply imputed dataset (supplementary data section 5, Tables 286 
S2 and S3). 287 
  288 
 
 
Discussion 289 
In this study we have shown flucloxacillin to be associated with 5.22 (95% CI 1.64-16.62) times the 1-290 
45 day risk of laboratory confirmed liver injury than oxytetracycline after multivariable adjustments, 291 
with an absolute 1-45 day risk of 8.47 (95% CI 6.64-10.65) per 100000 people prescribed the drug for 292 
the first time. There was strong evidence that increasing age and number of prescriptions were 293 
associated with increased flucloxacillin-induced liver injury, with those over the age of 70 who 294 
received at least one additional flucloxacillin prescription within 45 days of their initial prescription 295 
having a risk of jaundice of 110.57 per 100000 people (95% CI 66.35-154.79). 296 
Comparison with previous studies 297 
Our estimate of the overall risk of laboratory-confirmed liver injury is comparable to previously 298 
published risk estimates of 7.57 (95% CI 3.63-13.92)7 and 8.48 (95% CI 5.43-12.61).6 While previous 299 
studies have estimated the relative effect of age on risk to be between 18.61 (comparing over 55s 300 
versus under 30s)8 and 6.1 (comparing over 60 versus under 60),6 our large study is the first to 301 
estimate absolute risk figures by age categories, and has shown that those over 70 years of age 302 
experience the highest risk. We found a nine-fold increased risk in people given three or more 303 
flucloxacillin prescriptions compared with those given one prescription, also consistent with previous 304 
work showing that those with more than 14 consecutive days’ use have 7.13 times the risk of injury 305 
than people using for less than this period (95% CI 2.90-17.58).8 The size of our study has allowed us 306 
to demonstrate a dose(prescription)-response effect, and show that those over the aged of 70 who 307 
receive more than 1 prescription within the 1-45 day period have a particularly elevated risk. 308 
Implications and further work 309 
Current flucoxacillin prescribing information relating to hepatic side-effects1 states that (1) jaundice 310 
affects less than 1 in 10000 people and (2) the drug should be used cautiously in people over 50 311 
years of age.  Our results suggest that flucloxacillin causes jaundice at a frequency closer to 1 in 7000 312 
people in the overall population, that prolonged use is likely to increase the risk further, and those 313 
over the age of 70 have an approximately 15-fold higher risk than those under the age of 50. This is a 314 
particular concern when considering recent flucloxacillin prescribing trends showing that people 315 
over the age of 70 have both the highest prescribing rates and largest increase in rates.3 We would 316 
therefore hope that these findings could help physicians gain a greater understanding of the nature 317 
of the risk involved with prescribing flucloxacillin, and exercise caution in prescribing particularly 318 
long treatment courses to those over the age of 70. In a clinical setting the choice may be between 319 
flucloxacillin and another drug with known adverse effects on the liver – the absolute risk figures 320 
provided in our study would help inform clinicians’ prescribing decisions in this situation. 321 
 
 
In terms of a mechanism for an age-dependent increase in the risk of flucloxacillin-induced liver 322 
injury, it is plausible that impaired renal function in the elderly could increase drug concentrations.25 323 
Not all drugs associated with liver injury demonstrate a similar age-dependent increase in risk, 324 
however,26 suggesting an alternative mechanism. An increased use of concomitant hepatotoxins 325 
amongst the elderly has also been suggested as contributing to the observed increased risk,26 but in 326 
our study we adjusted for use of a large number of known hepatotoxins. We did observe that 327 
patients over the age of 70 had a higher proportion of cholestatic (versus hepatocellular) injury than 328 
those under 70 (consistent with previous studies on drug-induced liver injury),27, 28 and we hope this 329 
could help inform studies on the mechanism of flucloxacillin-induced liver injury in the future.    330 
We would also hope that our findings might help further development of a predictive genetic test 331 
and/or elucidation of mechanism via genetic association studies. Genetic analysis has demonstrated 332 
the HLA-B*5701 genotype to be a major determinant of drug-induced liver injury due to 333 
flucloxacillin.29 Despite this finding, subsequent consideration of clinical utility30 showed that (based 334 
on an overall population prevalence of 8.5 per 100000) predictive genetic testing for the reaction 335 
would be unfeasible, as 13513 people would need screened in order to prevent 1 case. Assuming 336 
that all of the cases of jaundice attributed to flucloxacillin in this study fulfil the criteria for DILI 337 
(which we consider a fair assumption, given how clear an indicator jaundice is of a serious liver 338 
problem), calculating the number needed to test within those over 70 using the drug reduces this 339 
number to 2512 (see supplementary data section 6).  Although still likely to be prohibitively high, 340 
further elucidation of characteristics associated with increased risk may allow the number needed to 341 
test to be reduced further for specific groups in the future. 342 
Limitations 343 
It is likely that older people will have more liver tests performed, meaning that ascertaiment bias 344 
could have affected our results. We found comparable results for jaundice-defined cases, however, 345 
making this an unlikely explanation for our results. There is no specific Read code or term to allow a 346 
clinician to record a case of drug-induced liver injury within CPRD, meaning that there was an 347 
element of clinical uncertainty around assigning case status. We attempted to overcome this by 348 
using a detailed algorithm based upon a literature search of diagnostic terms, defined standards for 349 
laboratory test patterns indicative of drug-induced liver injury and applying multiple case definitions. 350 
We were also able to demonstrate that 86% of the cases of liver injury that we attributed to 351 
flucloxacillin would have been assigned as “Probable” flucloxacillin-induced liver injury by the 352 
RUCAM/CIOMS causality assessment method (91% of those in the over 70 year-old age group).  353 
Improved coding and linkages with (e.g.) liver pathology databases could simplify this process in the 354 
future. Utilising existing linkages between CPRD and the UK Hospital Episodes Statistics database and 355 
Office of National Statistic mortality data could have allowed biopsy, scan and mortality data to be 356 
 
 
considered, which if combined with laboratory results can be used to support the diagnosis of drug-357 
induced liver injury.10 In a previous study, however, we found that an algorithm for detecting liver 358 
injury that included information on death and 11 different biopsy/scan procedure terms from these 359 
data sources provided only very limited improvement on the ability to detect cases (when compared 360 
to the use of diagnostic and biochemical criteria from CPRD alone).22 The use of our very broad 361 
definition (i.e. just jaundice) means that a small degree misclassification of outcome is possible. We 362 
used a very thorough process of review to rule out other causes of injury, however, and considered 363 
jaundice to be a clear marker of a serious liver problem. Furthermore, the choice not to use the 364 
linked datasets meant we had a larger sample size within which our stratified analyses had better 365 
power. 366 
Our causal analysis could have been impacted by confounding by indication. In order to assess the 367 
potential for this to occur, we tabulated the ten most common diagnostic terms entered on the 368 
index date for each drug (supplementary sata section 7). For both drugs the predominant diagnosis 369 
was a skin condition – acne for oxytetracycline, cellulitis/skin and subcutaneous tissue infections for 370 
flucloxacillin. As cirrhosis is a recognised risk factor for cellulitis,31 it is plausible that some of the liver 371 
injury observed in flucloxacillin users could be attributed to underlying cirrhosis. We consider this to 372 
be highly unlikely, however, due to the fact that (1) cirrhosis was included as an exclusion term in 373 
our study and (2) we performed a detailed (blinded) clinician review of medical records in the 6 374 
months prior to index date in order to rule out non-drug causes of injury.  We also believe that the 375 
strength of the association we observe is too large to be explained by confounding by indication.   376 
Finally, although we aimed to include participants based upon first-time use of the drugs under 377 
study, it is possible that patients may have been prescribed the drugs prior to registration with a 378 
General Practice (GP) contributing to CPRD, which could mean that our risk estimates are an 379 
underestimation of the true frequency within those prescribed flucloxacillin for the first time.  380 
Conclusions  381 
In the largest study of flucloxacillin-induced liver injury to date, we have provided new absolute risk 382 
estimates by age, number of prescriptions and gender for both laboratory-confirmed injury and 383 
jaundice, providing insight into groups particularly susceptible to harm, especially those aged over 384 
70 years receiving multiple prescriptions.  These results should help guide clinical care decisions and 385 
support further work on predictive genetic test implementation. 386 
 387 
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Table 1: Classification of drug-induced liver injury based on liver test results10 500 
Type of liver injury Liver test result 
Characteristic of any DILI ALT ≥ 5 x ULN or 
ALP ≥ 2 x ULN or 
ALT ≥ 3 x ULN and Bil > 2 x ULN 
Characteristic of hepatocellular type of DILI R* ≥ 5 
Characteristic of mixed type of DILI (=cholestatic 
hepatitis) 
R > 2 and < 5 
Characteristic of pure cholestatic type of DILI R ≤ 2 
*R=(ALT/ULN)/(ALP/ULN), where ALT=alanine aminotransferase, ALP=alkaline phosphatase, Bil=bilirubin and 
ULN=upper limit of normal 
 501 
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Figure 1: Overview of time windows used for case assignment and analysis performed for the 503 
exposed and comparator groups of the flucloxacillin and liver injury cohort study 504 
 
Overview of time windows applied for case assignment 
A. Minimum 6 months prior registraton required before Day 1 (=the index date, i.e. prescription for flucloxacillin or oxytetracycline) 
B. Within the 90 day period after the index date, all participants had their records searched for a liver-related diagnosis 
C. Case status assigned  based upon presence of liver-related diagnostic codes and DILI lab results. Examples shown as follows: 
1. Lab-confirmed 1-45 day case. Liver related diagnostic code other than jaundice found in the 1-45 period, DILI lab results found 
before day 46 so person is a lab-confirmed 1-45 day case. Case date=date of DILI lab results (as this occurs after the liver-related 
diagnostic code). Diagnostic code ≠ jaundice, therefore is not a symptom-defined case. 
2. 1-45 day non-case, symptom-defined 46-90 day case. No liver-related codes during day 1-45, diagnostic code recording 
jaundice in the 46-90 day period so person is a symptom-defined 46-90 day case. No lab test result indicating DILI within the 1-90 
day period, so person is not a lab-confirmed case. 
3. Symptom-defined 1-45 day case, lab-confirmed 46-90 day case. Person has a diagnostic code recording jaundice within the 1-
45 day period so is a symptom-defined 1-45 day case. Lab results indicating DILI also found within person’s record within 46-90 
day period, so person is a lab-defined 46-90 day case. Dates of the two separate case classifications are different. 
4. 1-45 day and 46-90 day non-case. Person does not have any liver-related diagnostic codes within the 1-90 day period. 
5. 1-45 day non-case, symptom-defined and lab-confirmed 46-90 day case. Person does not have a liver-related diagnostic code 
in the 1-45 day period so is a 1-45 day non-case. Person has a diagnostic code for jaundice in the 46-90 day period so is a 
symptom-defined 46-90 day case. Subsequent search of 90 day period for DILI lab results finds lab results qualifing as DILI in the 1-
45 day period so person is also a 46-90 day lab-confirmed case (with date of lab-confirmed case assignment being the latest of the 
DILI result date and diagnostic code dates). 
Estimation of absolute and relative effects 
Risk: 1-45 day risk calculations were performed by dividing the total number of 1-45 day cases by the total number of people in each 
group. Within those prescribed flucloxacillin who did not experience the specific classification of liver injury under study (symptom-
defined or lab-confirmed) in the 1-45 day period, the 46-90 day risk was also calculated.   
Risk ratio: Given the rarity of the outcome under study, an odds ratio was calculated and interpreted as a risk ratio 24. Risk ratios 
comparing the risk of liver injury during the 1-45 day period after a first prescription of flucloxacillin to the risk during the 1-45 day 
after a first prescription of oxytetracycline were calculated and presented. 
 505 
 
 
Figure 2: Flow of number of individuals included in the cohort study of the association between 506 
flucloxacillin (compared with oxytetracycline) and liver injury 507 
 508 
1Ineligible: had a diagnostic exclusion code or test result within 6 months prior to their index date, made up of: (i) 11089 509 
individuals with pregnancy codes but no subsequent end of pregnancy code before index date (ii) 13139 individuals with liver 510 
pathology codes as defined in the supplementary data (iii) 2928 individuals with liver test results that qualified as DILI 511 
as defined in the supplementary data. 512 
2Excluded: individuals identified as cases of liver injury, but on clinician review of record from 6 months prior to index 513 
date, an underlying cause other than a prescription with either of the drugs of interest was identified (and the date was prior to 514 
the index date). 515 
3Flucloxacillin: Number of people prescribed flucloxacillin on their index date. 47370/861959 were prescribed the flucloxacillin-516 
ampicillin combination (co-fluampicil). 517 
4Oxytetracycline: Number of individuals prescribed oxytetracycline on their index date who were not also prescribed 518 
flucloxacillin before the end of the 1-45 day risk period. Individuals who were also prescribed flucloxacillin before day 45 were 519 
assigned to the flucloxacillin group. 520 
  521 
Individuals in CPRD over the age of 18 prescribed one of the drugs under study 
between 01/01/2000 and 01/01/2012 with at least 6 months registration in CPRD 
prior to drug prescription (N=1073894)
Ineligible (n=27156)1
Flucloxacillin3 
(n=861962)
Total eligible individuals (N=1046738)
Excluded (n=39)2
Complete cohort (N=1046699)
Oxytetracycline4
(n=184737)
 
 
Table 2: Characteristics of participants included in the cohort analysis of the association between 522 
flucloxacillin (compared with oxytetracycline) and liver injury, by exposure status  523 
  Oxytetracycline  
(N = 184737) 
Flucloxacillin  
(N = 861962) 
  n (%) n (%) 
Age at index date Median (25 - 75%) 50 (35 – 65) 48 (34 – 65) 
    
Gender Male 81316 (44) 394125 (46) 
 Female 103421 (56) 467834 (54) 
    
Date of index prescription 2000 – 2001 32439 (17) 112188 (13) 
 2002 - 2003 34830 (19) 143752 (17) 
 2004 - 2005 32615 (18) 156808 (18) 
 2006 - 2007 30090 (16) 159304 (18) 
 2008 - 2009 29217 (16) 153679 (18) 
 2010 - 2011 25546 (14) 136228 (16) 
 
  
 
Prescriptions for other causes  None 34529 (19) 415687 (48) 
of liver injury1 Less common cause 143164 (77) 399846 (47) 
 More common cause 7044 (4) 46426 (5) 
 
  
 
Smoking status  Non-smoker 84864 (46) 382320 (44)  
Ex-smoker 40979 (22) 219122 (25) 
 Current smoker 55343 (30) 242314 (29) 
 Missing 3551 (2) 18203 (2) 
 
  
 
BMI  <20 10923 (6) 48451 (6)  
20 – 25 55689 (30) 247583 (29) 
 25+ 95215 (52) 447203 (52) 
 Missing 22910 (12) 118722 (13) 
 
  
 
Alcohol intake Non-drinker 20831 (11) 97065 (11)  
Ex-drinker 5581 (3) 28277 (3) 
 Current NOS 5852 (3) 27452 (3) 
 2 or less u/d 30424 (16) 139300 (16) 
 3/6 u/d 84057 (46) 381539 (44) 
 >6 u/d 13232 (7) 66576 (8) 
 Missing 24760 (14) 121750 (15) 
 
  
 
Socioeconomic status (SES) 1 (Highest SES) 33239 (18) 153552 (18)  
2 29919 (16) 145586 (17)  
3 27753 (15) 140223 (16)  
4 27541 (15) 131425 (15)  
5 (Lowest SES) 19122 (10) 102723 (12)  
Missing 47163 (26) 188450 (22) 
   
 
Ethnicity White 93400 (51) 440740 (51)  
South Asian 3010 (2) 14487 (2)  
Black 1445 (1) 8566 (1)  
Other 1470 (1) 6202 (1)  
Mixed 392 (0) 2238 (0)  
Not Stated 14390 (8) 70946 (8)  
Missing 70630 (37) 318780 (37) 
Note 1: Prescription counted if it occurred anytime from 1 month prior to index date or between index and before end of follow-up. Less or more 
common in relation to flucloxacillin, as reported in the literature. Note 2: Linked data, only available for practices in England, based on index of 
Multiple Deprivation (individual patient postcode) or otherwise practice level score based upon practice postcode (if no individual-level data). 
Note 3: Obtained from CPRD, unless none found, in which case from HES if patient from a linked practice.  
 524 
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Table 3: (1) 1-45 day risk of liver injury by exposure to flucloxacillin or oxytetracycline and (2) crude and multivariable adjusted risk ratios (RR) (comparing the 526 
flucloxacillin 1-45 day period with the oxytetracycline 1-45 day period) 527 
Case definition1 Exposure group # with 
outcome 
People 45-day risk (CI2) 
(per 100 000 patients 
prescribed the drug) 
Crude RR (CI) Multivariable RR3 (CI) 
Symptom-based only Oxytetracycline 1 - 45 days 7 184737 3.79 (1.52 – 7.81) 1 1  
Flucloxacillin 1 - 45 days 122 861962 14.15 (11.75 – 16.92) 3.74 (1.74 – 8.00) 3.73 (1.73 – 8.03) 
       
Laboratory-confirmed Oxytetracycline 1 - 45 days <53 184737 1.62 (3.35 – 4.75) 1 1 
 Flucloxacillin 1 - 45 days 73 861962 8.47 (6.64 – 10.65) 5.22 (1.65 – 16.57) 5.22 (1.64 – 16.62) 
Note 1: Symptom based only: diagnostic code for jaundice present within the 45-day risk period being analysed. Laboratory-confirmed: both of the following present within the 45-day risk period being 
analysed: (1) any of the diagnostic codes listed in supplementary data section 3 and (2) liver test results indicating drug-induced liver injury (according to Aithal et al).   Both definitions: all other more 
likely causes of the liver symptoms ruled out by clinician review of full electronic health record in the 6-month period before the case date Note 2: 95% confidence interval. Note 3: Adjusted for age, 
gender, date of index prescription, prescriptions for other drugs likely to cause liver injury, smoking status, BMI, alcohol intake, socioeconomic status and ethnicity. Missing covariate data taken account 
of using multiple imputation by chained equations, with all available variables included in the multiple imputation model. 
 528 
 
 
Table 4: Risks and multivariable adjusted risk ratios (RR) for liver injury within those exposed to 529 
flucloxacillin (for the 1-45 day period after exposure) for laboratory and symptom-based cases by 530 
potential risk factors age, gender and number of prescriptions 531 
Case definition1 
 
Risk factor  # with 
outcome 
People 
 
Risk2 (CI3) Multivariable RR4 (CI) 
Symptom-based only 
(n=122) 
Age 18 – 49 13 453636 2.87 (1.53 – 4.90) 16 
 50 – 59 19 129179 14.71 (8.86 – 22.97) 5.02 (2.47 – 10.19) 
 60 – 69 14 111368 12.57 (6.87 – 21.09) 4.18 (1.95 – 8.99) 
 70 – 79 41 91443 44.84 (32.18 – 60.82) 14.31 (7.51 – 27.26) 
 80+ 35 76336 45.85 (31.94 – 63.76) 13.87 (7.16 – 26.86) 
Gender Male 43 394126 10.91 (7.90 – 14.70) 1 
 Female 79 467836 16.89 (13.37 – 21.04) 1.43 (0.98 – 2.08) 
No. of prescrs 1 88 777353 11.45 (9.19 – 14.09) 16 
 2 26 74431 33.59 (21.74 – 49.58) 2.45 (1.57 – 3.82) 
 3+ 8 10178 78.60 (33.94 – 154.82) 5.06 (2.44 – 10.46) 
Laboratory-
confirmed (n=73) 
Age 18 – 49 4 453636 0.89 (0.24 – 2.26) 16 
 50 – 59 13 129179 10.06 (5.36 – 17.21) 10.79 (3.50 – 33.19) 
 60 – 69 10 111368 8.97 (4.31 – 16.51) 8.83 (2.74 – 28.50) 
 70 – 79 23 91443 25.15 (15.95 – 37.74) 23.26 (7.88 – 68.67) 
 80+ 23 76336 30.13 (19.10 – 45.21) 25.42 (8.58 – 75.33) 
Gender Male 24 394126 6.09 (3.90 – 9.06) 1 
 Female 49 467836 10.47 (7.75 – 13.85) 1.61 (0.98 – 2.65) 
No. of prescrs 1 46 777353 5.92 (4.33 – 7.89) 16 
 2 19 74431 25.53 (15.37 – 39.86) 3.50 (2.05 – 6.00) 
 3+ 8 10178 78.60 (33.94 – 154.82) 9.37 (4.40 – 19.95) 
Note 1: Symptom based only: diagnostic code for jaundice present within 1-45 day risk period. Laboratory-confirmed: both of the following 
present within the 1-45 day risk period: (1) any of the diagnostic codes listed in supplementary data section 3 and (2) liver test results 
indicating drug-induced liver injury (according to Aithal et al). Both definitions: all other more likely causes of the liver symptoms ruled out 
by clinician review of full electronic health record in the 6 months period before the case date. Note 2: Per 100000 people prescribed 
flucloxacillin. Note 3: 95% confidence interval.  Note 4: Adjusted for date of index prescription, concomitant therapies for drugs considered 
to be causes of liver injury and all other variables in this table. Note 5: p-value(test for trend )<0.001 
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Figure 3: Illustration of change in absolute risk of flucloxacillin-induced liver injury by (a) increasing 534 
age (for both jaundice and laboratory confirmed outcomes) and (b) increasing number of 535 
prescriptions (for jaundice, showing B1: overall risk and B2: risk within those over the age of 70) 536 
 
  
 Note 1: Upper-limit of 95% CI for 3+ category=381.9  
 537 
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